Physician profile
John B Wright
NPI 1417970047
$3,490.61
in general payments reported to CMS, 2019-2025
22 companies · $654 in 2025
The $654 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $212 · 2021: $358 · 2022: $507 · 2023: $827 · 2024: $759 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Entertainment: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.67 |
| Entertainment | $298.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $564.72 | 2022-2025 | Infuse, Vyzulta, Lotemax Sm |
| Glaukos Corporation | $478.44 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Alcon Vision LLC | $377.99 | 2020-2025 | Precision 1, Tryptyr, Total30 |
| Johnson & Johnson Vision Care, INC. | $352.78 | 2019-2025 | Acuvue |
| Optos, INC. | $298.46 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $248.44 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.81 | 2019-2021 | |
| Coopervision INC. | $145.45 | 2023-2024 | Myday Contact Lens |
| Eyevance Pharmaceuticals LLC | $138.40 | 2019-2022 | |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $114.84 | 2022-2025 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $114.15 | 2023 | Spectacle Lenses, Contact Lens |
| Novartis Pharmaceuticals Corporation | $69.76 | 2019-2022 | |
| Abbvie INC. | $65.67 | 2022-2023 | Lumigan, Alphagan P |
| Allergan, INC. | $36.53 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $34.13 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $33.24 | 2025 | Xdemvy |
| Dompe US, INC. | $27.76 | 2025 | Oxervate |
| Biotissue Holdings INC. | $26.21 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.48 | 2019 | |
| Thea Pharma INC. | $24.08 | 2025 | Iyuzeh |
| Sight Sciences, INC. | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.